Korea S.E.
03:30:00 16/07/2024 am IST
5-day change
1st Jan Change
20,800
KRW
-0.95%
-1.89%
-9.17%
Seegene, Inc.'s Equity Buyback Plan Extended till July 14, 2025.
On July 12, 2024, the company announced that it has extended its plan duration till July 14, 2025.
Seegene, Inc.'s Equity Buyback Plan Extended till July 14, 2025.
12/07
CI
Seegene, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
16/05
CI
Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
14/03
CI
Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases
24/01
CI
Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy; Expanded Collaboration Aims To Improve Syndromic Infectious Disease Testing
14/12
MT
Microbix Brief: Microbix and Seegene USA Jointly Enhancing Lab Test Accuracy
14/12
MT
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
14/11
CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on July 13, 2023.
13/23/13
CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023.
28/23/28
CI
Seegene, Inc.'s Equity Buyback announced on February 28, 2023, has expired with 2,046,354 shares, representing 4.11% for KRW 49,998.4 million.
28/23/28
CI
Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
14/23/14
CI
Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC
31/23/31
CI
Seegene, Inc. announces an Equity Buyback for KRW 30,000 million worth of its shares.
13/23/13
CI
Seegene, Inc. authorizes a Buyback Plan.
13/23/13
CI
Seegene, Inc. and Werfen Partner to Collaborate on Onesystem Business to Develop Syndromic qPCR Assays
14/23/14
CI
Seegene and Werfen Partner to Collaborate on OneSystem(TM) Business to Develop Syndromic qPCR Assays
14/23/14
CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on February 28, 2023.
30/23/30
CI
Seegene, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/23/15
CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022.
28/23/28
CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022.
28/23/28
CI
Seegene, Inc.'s Equity Buyback announced on September 28, 2022, has expired with 1,780,608 shares, representing 3.56% for KRW 49,330.84 million.
28/23/28
CI
Seegene, Inc. announces an Equity Buyback for KRW 50,000 million worth of its shares.
28/23/28
CI
Seegene, Inc. authorizes a Buyback Plan.
28/23/28
CI
Tranche Update on Seegene, Inc.'s Equity Buyback Plan announced on September 28, 2022.
30/22/30
CI
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
14/22/14
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Seegene Inc is a Korea-based company engaged in the development, manufacturing and distribution of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other inspection products, drug resistance inspection products, single nucleotide polymorphisms (SNP) inspection products, as well as somatic mutation cancer inspection products. In addition, it is involved in the provision of automatic real-time detection instruments. The Company provides its products under the brand names of Seeplex, Anyplex and Magicplex. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-9.17% 702M -32.86% 8.68B +25.06% 3.86B +15.74% 2.43B -26.46% 1.84B -7.09% 1.73B +40.61% 1.16B +54.75% 842M -9.18% 594M -19.58% 239M
Bio Diagnostics & Testing
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SEEGENE, INC. 
